COMP <GO>
BCTX vs FLNA // FORWARD P/E MULTIPLE
BriaCell Therapeutics Corp. (NASDAQ) VS. Filana Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: BCTX 1
— FLNA 2
■ METRIC PARITY
LAST: $3.01 (-2.59%) • MKT CAP: $27.0M
forward-pe
—
LAST: $0.59 (+5.94%) • MKT CAP: $27.1M
forward-pe
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BCTX VS. FLNA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BCTX | FLNA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 2/9 | -1.00 | FLNA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.4 | 33.8 | +3.60 | BCTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $27.0M | $27.1M | -$117.7K | FLNA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BCTX REV | FLNA REV | BCTX GROSS % | FLNA GROSS % | BCTX FCF | FLNA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $76.2M | $267.1M | — | — | -$28.2M | -$32.8M |
| FY 2024 | $93.3M | $396.0M | — | — | -$24.6M | -$117.0M |
| FY 2023 | $65.2M | $296.7M | — | — | -$23.7M | -$82.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BCTX // BETA —
FLNA // BETA —